Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJ NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$254.64+4.0%$230.92$151.01▼$255.11$589.48B0.268.46 million shs16.31 million shsNVAXNovavax$8.88+3.7%$9.14$6.20▼$11.97$1.41B2.454.35 million shs8.40 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson+3.96%+11.51%+10.06%+5.93%+67.16%NVAXNovavax+3.74%-2.74%-19.93%+5.09%+37.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$254.64+4.0%$230.92$151.01▼$255.11$589.48B0.268.46 million shs16.31 million shsNVAXNovavax$8.88+3.7%$9.14$6.20▼$11.97$1.41B2.454.35 million shs8.40 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson+3.96%+11.51%+10.06%+5.93%+67.16%NVAXNovavax+3.74%-2.74%-19.93%+5.09%+37.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.74Moderate Buy$256.700.81% UpsideNVAXNovavax 2.22Hold$13.0046.40% UpsideCurrent Analyst Ratings BreakdownLatest NVAX and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$270.006/26/2026JNJJohnson & Johnson GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$266.00 ➝ $270.006/15/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/11/2026NVAXNovavax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.005/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.005/7/2026NVAXNovavax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/6/2026NVAXNovavax TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$8.00 ➝ $9.004/24/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)4/20/2026JNJJohnson & Johnson GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$244.00 ➝ $266.004/16/2026JNJJohnson & Johnson ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$240.00 ➝ $275.00(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$94.19B6.51$14.69 per share17.34$33.85 per share7.52NVAXNovavax$1.12B1.30$3.64 per share2.44($0.79) per share-11.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$26.80B$8.6529.4420.212.4021.83%32.60%13.29%7/15/2026 (Estimated)NVAXNovavax$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)Latest NVAX and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/15/2026Q2 2026JNJJohnson & Johnson$2.83N/AN/AN/A$24.96 billionN/A5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$5.362.10%+5.25%61.97%64 YearsNVAXNovavaxN/AN/AN/AN/AN/ALatest NVAX and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.33%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.461.030.77NVAXNovavaxN/A2.482.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%NVAXNovavax1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableNVAXNovavax1,990164.44 million161.81 millionOptionableNVAX and JNJ HeadlinesRecent News About These CompaniesNovavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts2 hours ago | americanbankingnews.comNovavax Inc. stock underperforms Friday when compared to competitors despite daily gainsJune 26 at 10:43 PM | marketwatch.comNovavax (NVAX) Suffers a Larger Drop Than the General Market: Key InsightsJune 24 at 8:07 PM | finance.yahoo.comNovavax (NVAX) Suffers a Larger Drop Than the General Market: Key InsightsJune 24 at 6:47 PM | zacks.comNovavax faces renewed attack by Shah Capital after AGMJune 24 at 10:05 AM | msn.comShah Capital Responds to Significant Shareholder Dissent at Novavax AGMJune 24 at 10:05 AM | finance.yahoo.comShah Capital Responds to Significant Shareholder Dissent at Novavax AGMJune 24 at 8:00 AM | globenewswire.comInvestors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowJune 23, 2026 | finance.yahoo.comInvestors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowJune 23, 2026 | zacks.comNovavax Shareholders Approve Directors, Pay and Incentive PlansJune 23, 2026 | tipranks.comNovavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to KnowJune 18, 2026 | finance.yahoo.comNovavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to KnowJune 18, 2026 | zacks.comModerna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?June 16, 2026 | 247wallst.comModerna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?June 16, 2026 | 247wallst.comA Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The PackJune 16, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)June 14, 2026 | theglobeandmail.comNovavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You TradeJune 12, 2026 | finance.yahoo.comNovavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You TradeJune 12, 2026 | zacks.comNovavax Pivots To Matrix M Licensing As Sanofi Takes EuropeJune 10, 2026 | finance.yahoo.comNovavax rises after six sessions of declineJune 9, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Mission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 20263 Dividend Kings That Earn Their Crown Every QuarterBy Chris Markoch | May 31, 2026NVAX and JNJ Company DescriptionsJohnson & Johnson NYSE:JNJ$254.64 +9.76 (+3.99%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$254.38 -0.26 (-0.10%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novavax NASDAQ:NVAX$8.88 +0.32 (+3.74%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$8.85 -0.03 (-0.29%) As of 06/26/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
